Premium
Effects of CO liberated from carbon monoxide‐releasing molecule (CORM)‐2 on modulation of inflammatory response in ischemia/reperfusion (I/R)‐challenged small intestine
Author(s) -
Katada Kazuhiro,
Bihari Aurelia,
Stephen Jancy,
Badhwar Amit,
Potter Richard F.,
Cepinskas Gediminas
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.730.5
Subject(s) - small intestine , jejunum , chemistry , intravital microscopy , corm , inflammation , ischemia , myeloperoxidase , western blot , pharmacology , microcirculation , medicine , endocrinology , immunology , pathology , biochemistry , biology , gene , agronomy
CORM‐released CO has been shown to modulate inflammatory response. In this study, we assessed the effects and potential mechanisms of CORM‐2‐released CO on modulation of inflammatory response in mice small intestine following I/R. To this end mice (C57Bl/6) small intestine were challenged with ischemia by occluding SMA for 45 min. CORM‐2 (8 mg/kg; i.v.) was administered: 1) immediately before SMA occlusion or 2) immediately upon reperfusion. Sham operated mice were injected with vehicle (DMSO). Inflammatory response in the small intestine was assessed by measuring tissue levels of TNF‐[alpha] (ELISA), iNOS, ICAM‐1, and E‐selectin (Western blot) protein, accumulation of PMN (MPO assay) and the number of rolling/adherent leukocytes in the microcirculation of jejunum mucosa (Intravital microscopy) 4 hr following reperfusion. The obtained results indicate that tissue levels of TNF‐[alpha], iNOS, ICAM‐1 and E‐selectin protein expression and subsequent PMN accumulation were elevated in I/R‐challenged jejunum. The above changes were significantly attenuated in CORM‐2‐treated mice. The most potent inhibition was observed in mice, which were injected with CORM‐2 immediately before induction of ischemia. Taken together these findings indicate that CORM‐2‐released CO confers anti‐inflammatory effects in I/R‐challenged small intestine (HSFO‐NA5580 and MOP‐68848).